Q-omics provides the consensus-scored PRDM16 profile across patient tissues and cancer cell-line models. PRDM16 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRDM16 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PRDM16 RNA expression shows 17,393 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where PRDM16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDM16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDM16 survival associations across molecular data types. PRDM16 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (11) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDM16 RNA expression–survival associations across cancer types. High PRDM16 expression shows unfavorable associations in KIRP, UVM, ACC and LGG, but favorable associations in KIRC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRDM16 RNA expression.
This table summarizes PRDM16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PRDM16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDM16 shows lower tumor expression in KIRC, KIRP, THCA, LUAD, LUSC and UCEC. The KIRC box plot shows higher PRDM16 RNA expression in normal versus tumor tissue (log2 FC = −3.017, t-test p < 0.001).
This table shows molecular features associated with PRDM16 in patient tissues and cancer cell lines. In patient samples, PRDM16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDM16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
